RecruitingPhase 4NCT06411925

The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients

A Multi-center, Randomized, Double-blinded, Active-controlled, Non-inferiority, Phase 4 Trial to Evaluate the Efficacy and Safety of Atock Dry Syrup Sama With Acute Bronchitis Patients

Sponsor

SamA Pharmaceutical Co., Ltd

Enrollment

296 participants

Start Date

Nov 10, 2023

Study Type

INTERVENTIONAL

Conditions

Acute Bronchitis

Summary

Clinical Study to Evaluate the Efficacy and Safety of Atock Dry Syrup with Acute bronchial Patients

Eligibility

Min Age: 6 MonthsMax Age: 11 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Atock Dry Syrup with placebo patch and a drug called Tulobuterol patch with placebo dry syrup for people with acute bronchitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 6 Months to 11 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAtock Dry Syrup with placebo patch

Atock Dry syrup (TID) with placebo patch (QD)

DRUGTulobuterol patch with placebo dry syrup

Tulobuterol patch (QD) with placebo dry syrup (TID)

Locations(1)

Soonchunhyang University Seoul Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06411925

Related Trials

Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients

NCT0765022733 locations

Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care

NCT073592871 location